Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment tags : Alliances save search
EVOTEC AND VARIANT BIO ENTER STRATEGIC PARTNERSHIP TO DISCOVER AND DEVELOP FIBROSIS TREATMENTS
Published: 2024-04-18 (Crawled : 13:00) - biospace.com/
EVO | $7.15 -0.7% 19K
|
Manufacturing
|
| O: 0.42%
H: 0.0%
C: 0.0%
partnership fibrosis
Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases
Published: 2024-01-09 (Crawled : 13:30) - biospace.com/
TGTX | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
|
| O: -8.22%
H: 9.05%
C: 7.47%
DTIL | $9.75 -9.05% -9.95% 170K
|
Health Technology
|
| O: 10.0%
H: 14.23%
C: 0.09%
license cell treatment deal therapeutics therapy
Tryp Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial for the Treatment of Fibromyalgia at The University of Michigan
Published: 2024-01-04 (Crawled : 00:00) - biospace.com/
CYBN | $0.3677 -0.6% 0.35% 1.8M
|
n/a
|
| O: 0.65%
H: 3.49%
C: 3.49%
first fibromyalgia treatment trial therapeutics
Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer
Published: 2023-12-11 (Crawled : 14:30) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 1.06%
H: 0.59%
C: -0.46%
MRNA S | $101.44 -0.55% -0.55% 2.6M
|
Health Technology
|
| O: -0.47%
H: 3.28%
C: 2.58%
rna-4157 keytruda lung merck cancer cell treatment study
Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)
Published: 2023-12-06 (Crawled : 17:00) - biospace.com/
COYA | $7.87 -6.75% -7.24% 54K
|
|
| O: 5.91%
H: 3.76%
C: -6.1%
sclerosis treatment collaboration commercialization therapy
Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease
Published: 2023-12-06 (Crawled : 14:30) - biospace.com/
FBIO | $1.765 -2.49% -2.55% 190K
|
Health Technology
|
| O: 0.75%
H: 7.43%
C: 4.09%
cutx-101 candidate disease biotech transfer treatment
Odyssey Health, Inc, Selects Syneos Health to Support Investigational New Drug Application for Treatment of Concussion
Published: 2023-11-16 (Crawled : 14:30) - biospace.com/
ODYY | $0.0337 354.55% 500
|
Manufacturing
|
| O: 0.39%
H: 3.49%
C: 3.49%
drug health treatment application
Thermo Fisher Scientific Signs Companion Diagnostic Agreement with Boehringer Ingelheim to Select Patients with NSCLC for Targeted Therapy Treatment
Published: 2023-10-19 (Crawled : 13:30) - biospace.com/
TMO | News | $544.78 0.6% 0.0% 1.7M
|
Health Technology
|
| O: -2.02%
H: 0.0%
C: 0.0%
diagnostic treatment companion agreement therapy
Sonendo Announces New Partnership Agreements with Two Leading Specialty DSOs to Expand Access to the GentleWave® Procedure for Elevated Root Canal Treatment
Published: 2023-10-04 (Crawled : 13:00) - biospace.com/
SONX S | $0.0884 3.6% 180K
|
Manufacturing
|
| O: 25.0%
H: 0.0%
C: -22.5%
gentlewave partnership treatment sonendo root
Path for BrainStorm ALS Treatment Remains Rocky, Hope for Others on the Horiz...
Published: 2023-09-29 (Crawled : 21:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320
|
Communications
| Email alert
Add to watchlist
als hope treatment
Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis PatientsApproval triggers $1.5 million milestone payment to Cara
Published: 2023-09-25 (Crawled : 13:00) - biospace.com/
CARA | $0.6816 -1.22% -1.23% 350K
|
Health Technology
|
| O: 1.8%
H: 4.12%
C: 0.59%
korsuva pruritus japan hemodialysis approval payment treatment therapeutics injection milestone
US FDA approves Jardiance® for the treatment of adults with chronic kidney disease
Published: 2023-09-22 (Crawled : 15:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -2.93%
H: 1.22%
C: 0.32%
jardiance fda disease kidney treatment
HyBryte™ Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment
Published: 2023-08-10 (Crawled : 13:00) - biospace.com/
SNGX | $0.4233 -2.76% -2.83% 1M
|
Health Technology
|
| O: 0.02%
H: 0.37%
C: -2.78%
t-cell treatment trial
Menarini Group Receives Positive CHMP Opinion Recommending EC Approval of ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2
Published: 2023-07-21 (Crawled : 13:00) - biospace.com/
RDUS | $18.41 -0.61% -0.61% 220K
|
Health Technology
|
| O: 0.21%
H: 0.67%
C: -0.98%
orserdu chmp her2 approval positive group treatment
LYNPARZA® (olaparib) plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer
Published: 2023-06-01 (Crawled : 13:20) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320
|
Communications
| Email alert
Add to watchlist
lynparza approved cancer treatment plus
Guardant Health and Parker Institute for Cancer Immunotherapy (PICI) launch research collaboration to study connection between cancer biomarkers and immunotherapy treatment response
Published: 2023-04-25 (Crawled : 14:00) - biospace.com/
GH M | $16.08 -3.54% -3.67% 1.9M
|
Health Services
|
| O: -0.95%
H: 0.0%
C: -6.13%
institute health cancer treatment research immunotherapy collaboration response biomarkers study
Celanese Announces Agreement with Glaukos Corporation for Sustained Release Glaucoma Treatment
Published: 2023-04-05 (Crawled : 16:00) - biospace.com/
GKOS | $96.5 1.44% 0.0% 700K
|
Health Technology
|
| O: -0.52%
H: 0.5%
C: -2.86%
CE | $154.45 -0.11% 0.0% 520K
|
Process Industries
|
| O: -0.97%
H: 1.63%
C: 1.52%
glaucoma corporation treatment agreement
Celanese Announces Collaboration with Alessa Therapeutics for the Advancement of Oncology Treatments
Published: 2023-03-01 (Crawled : 16:00) - biospace.com/
CE | $154.45 -0.11% 0.0% 520K
|
Process Industries
|
| O: 0.07%
H: 4.6%
C: 2.92%
collaboration therapeutics
ACE-Breast-02 Pivotal Phase 3 Study of Ambrx’s ARX788 for the Treatment of HER2 Positive Metastatic Breast Cancer Achieves Positive Results
Published: 2023-03-01 (Crawled : 14:00) - biospace.com/
AMAM 4 | $28.0 0.0% 1.4M
|
Professional, Scientific, and T...
|
| O: -0.93%
H: 8.16%
C: -7.54%
arx788 treatment breast positive cancer study her2 antibody-as269 metastatic breast cancer
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease
Published: 2023-02-24 (Crawled : 21:00) - biospace.com/
PLX | $1.15 1.77% -2.61% 450K
|
Health Services
|
| O: 0.59%
H: 15.2%
C: 6.43%
treatment rare global disease chmp positive
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.